Institute for Pulmonology Hagen Ambrock eV
Georg Nilius, Prof DR with
Controlled randomized crossover trial in patients with chronic obstructive respiratory disease (COPD), who are treated with Nasal High Flow (NHF) therapy during wakefulness with a small amount of CO2 added to the inhaled air to keep the patients' PaCO2 stable despite the washout effect. Aim of the study is to examine respiratory rate, tidal volume and work of breathing under NHF without the CO2 washout effect.
COPD
Nasal High Flow (NHF)
NA
In this controlled randomized crossover trial, 10 stable patients with chronic obstructive respiratory disease (COPD) are treated with Nasal High Flow (NHF) therapy during wakefulness. NHF treatment will inevitably result in increased upper airway washout and thus in a slight reduction of PaCO2 of approximately 2 mmHg. For compensation, a small amount of CO2 is added to the inhaled air during this experimental situation, which keeps the patients' PaCO2 stable. This will allow to examine the effects of NHF therapy on respiratory rate, tidal volume and work of breathing, that are not attributable to the CO2 washout effect.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 10 participants |
| Masking : | NONE |
| Primary Purpose : | BASIC_SCIENCE |
| Official Title : | Nasal High Flow (NHF) in COPD - Effects on ventilation while awake |
| Actual Study Start Date : | 2021-02-27 |
| Estimated Primary Completion Date : | 2021-11-12 |
| Estimated Study Completion Date : | 2022-03-01 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Evang. Kliniken Essen-Mitte gGmbH
Essen, NRW, Germany, 45276